GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company focused on treating itching. Its price chart is a dramatic story of the clinical failures of its lead drug, which led to a stock collapse and exemplifies binary risks in biotech.
Share prices of companies in the market segment - Neuro
Cara Therapeutics is a biopharmaceutical company focused on developing and commercializing drugs to treat itching associated with chronic diseases. We've categorized it as a Neuroscience company. The chart below shows how investors value companies operating in this niche.
Broad Market Index - GURU.Markets
Cara Therapeutics is a biopharmaceutical company developing treatments for itching associated with chronic diseases. Its unique niche makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Cara Therapeutics compares to it.
Change in the price of a company, segment, and market as a whole per day
CARA - Daily change in the company's share price Cara Therapeutics Inc.
Cara Therapeutics, Inc.'s daily stock price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its anti-itch drugs.
Daily change in the price of a set of shares in a market segment - Neuro
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. This is a highly specialized and risky niche in the pharmaceutical industry. The chart below illustrates the volatility in this sector, reflecting the high stakes associated with new drug development.
Daily change in the price of a broad market stock, index - GURU.Markets
Cara Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture-backed bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cara Therapeutics Inc.
For Cara Therapeutics, year-over-year performance is a story about the commercialization of its drug for the treatment of pruritus in dialysis patients. Its market capitalization change over the 12 months reflects the drug's sales volume, as well as the results of clinical trials for its use in other conditions, which is key to expanding the potential market.
Annual dynamics of market capitalization of the market segment - Neuro
Cara Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of pruritus. Its success hinges on the commercialization of its first approved drug. The chart below shows how its narrow focus, competitive environment, and efforts to expand its drug's applicability impact its volatile performance.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cara Therapeutics, a biotech company, demonstrates the roller coaster of drug development. Its chart, compared to the market, is a story of upswings driven by positive data and downswings driven by clinical trial failures. Economics are irrelevant here; research results decide everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cara Therapeutics Inc.
Cara is a biopharmaceutical company focused on the treatment of pruritus. Its monthly performance reflects both sales of its approved drug and, to a large extent, the results of clinical trials to expand its use and introduce new drugs.
Monthly dynamics of market capitalization of the market segment - Neuro
Cara Therapeutics develops drugs to treat itching associated with chronic diseases, such as kidney disease. This is a niche but important segment of neurology and dermatology. The chart below shows how investors assessed the prospects of companies focused on treating symptoms that significantly impair patients' quality of life.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cara Therapeutics is a biotech company developing drugs to treat itching. This is a highly specialized area. Share price performance depends on clinical trial results and the potential market size for its drugs, rather than on general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company focused on treating itching associated with chronic diseases. Its weekly stock price is volatile and depends on the results of clinical trials and the commercial success of its approved drug.
Weekly dynamics of market capitalization of the market segment - Neuro
Cara Therapeutics develops non-addictive drugs for the treatment of itching and pain, an important niche in neuroscience. The chart below helps determine whether the company's weekly stock price fluctuations reflect its own clinical data or reflect general investor sentiment in the pain relief industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cara Therapeutics is a clinical-stage biotech. Its shares move based on research results, not macroeconomics. This chart clearly demonstrates how the company's performance is disconnected from the stock market and driven by its own scientific cycle.
Market capitalization of the company, segment and market as a whole
CARA - Market capitalization of the company Cara Therapeutics Inc.
Cara Therapeutics' market capitalization is a story of biotech disappointment. Its sharp decline reflects the failure of its lead drug candidate in key clinical trials. The current low valuation reflects investor skepticism about the remaining pipeline and its ability to recover from this setback.
CARA - Share of the company's market capitalization Cara Therapeutics Inc. within the market segment - Neuro
Cara Therapeutics specializes in itch treatments, making it a niche player in neuroscience. Its share of the biotech sector's market capitalization is directly dependent on the success of its developments. The chart provides an indication of the market's confidence in the commercial potential of its unique therapeutic platform.
Market capitalization of the market segment - Neuro
Here's a chart showing the market capitalization of the neurological pharmaceuticals sector. Cara Therapeutics specializes in treating itching associated with chronic diseases. The dynamics of this market reflect the search for solutions to previously ignored but distressing symptoms. Cara is betting that its unique approach to this problem will be in demand.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cara Therapeutics is a biopharmaceutical company focused on developing treatments for pruritus associated with chronic diseases. Its market capitalization reflects its niche expertise. The chart below shows the economic weight of companies that improve quality of life.
Book value capitalization of the company, segment and market as a whole
CARA - Book value capitalization of the company Cara Therapeutics Inc.
Cara Therapeutics' foundation is its intellectual property for drugs targeting peripheral kappa opioid receptors for the treatment of pruritus. Its book value represents the capital it uses to conduct clinical trials. The graph tells the story of a biotech company that, after the approval of one product, is seeking new applications for its unique technology.
CARA - Share of the company's book capitalization Cara Therapeutics Inc. within the market segment - Neuro
Cara Therapeutics focuses on treating itching, and its strength lies in its intellectual property. The chart shows its share of actual R&D assets. These are its laboratories where research is conducted, providing the foundation for the development of innovative non-narcotic analgesics.
Market segment balance sheet capitalization - Neuro
Cara Therapeutics is a biopharmaceutical company working on the treatment of neurological disorders. Their primary assets are their research and patents, not their manufacturing capacity. A book value chart reveals their modest R&D base, which is merely the tip of the iceberg of their scientific potential.
Book value of all companies included in the broad market index - GURU.Markets
Cara Therapeutics' assets include laboratories and R&D centers where the innovative anti-itch drug was developed. The chart shows how the company built its scientific and material capital to commercialize its discovery and further research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cara Therapeutics Inc.
Cara Therapeutics is developing drugs for pain and itching, which are intangible assets until approved. The chart clearly demonstrates how the market capitalization based on the potential of one or two drug candidates can be many times greater than the modest book value of the laboratories and equipment.
Market to book capitalization ratio in a market segment - Neuro
Cara Therapeutics develops drugs for the treatment of neurological disorders. Like many biotech companies, its valuation is based on its research and development potential, not its manufacturing footprint. The chart shows a high premium to its book valuation, reflecting investor expectations for the success of clinical trials and future revenue from new drugs.
Market to book capitalization ratio for the market as a whole
Cara Therapeutics develops drugs in neuroscience. Its valuation depends almost entirely on the success of clinical trials. This metric demonstrates the extent to which investor expectations for future drugs exceed the company's current asset value. A high metric reflects market optimism about its scientific potential.
Debts of the company, segment and market as a whole
CARA - Company debts Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company facing a difficult period following clinical trial failures. This chart reflects its current financial survival strategy. The company is managing its remaining capital by cutting expenses and focusing on the most promising programs, which requires strict financial discipline.
Market segment debts - Neuro
Cara Therapeutics develops new treatments for itching associated with chronic diseases. Biotech research is a marathon, requiring constant R&D funding. This chart helps assess how the company's financial strategy balances the high risks and potential rewards of its niche.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cara Therapeutics Inc.
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on neuroscience. This chart shows its financial structure. For a company whose drugs have not yet reached the market, any debt is a significant risk. Failure in clinical trials would make it impossible to service.
Market segment debt to market segment book capitalization - Neuro
Cara Therapeutics is a biopharmaceutical company focused on treating neurological disorders. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its clinical research and the commercialization of drugs in this specific niche.
Debt to book value of all companies in the market
Cara Therapeutics develops drugs to treat neurological diseases. The long journey from the lab to the pharmacy requires a constant influx of capital. This chart, showing the overall market appetite for debt risk, is an indicator of how favorable the environment is for the company to raise funds for its expensive clinical trials.
P/E of the company, segment and market as a whole
P/E - Cara Therapeutics Inc.
Cara Therapeutics specializes in developing drugs that target peripheral kappa opioid receptors to treat itching and pain, but without the side effects of traditional opioids. This chart reflects the high risks and volatility of the biotech sector, where momentum depends entirely on clinical trial results.
P/E of the market segment - Neuro
Cara Therapeutics is a biopharmaceutical company focused on developing drugs to treat itching associated with chronic diseases, particularly kidney disease. This condition has few effective treatments. This chart shows the average valuation for the neuroscience sector, reflecting how investors value companies addressing unmet medical needs.
P/E of the market as a whole
Cara Therapeutics is a biopharmaceutical company developing drugs to treat itching. Its valuation depends entirely on the success of its clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant. Cara's fate is decided by clinical data reports, not inflation reports.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cara Therapeutics Inc.
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. This chart shows analysts' expectations for future revenue, which hinge on the success of its lead drug. These forecasts are based on the potential for commercialization of a first-in-class drug to alleviate this debilitating symptom.
%20P%2FE%20Cara%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cara-Therapeutics-Inc.&v=1772702451782 "Chart of the company's future (projected) P/E Cara Therapeutics Inc.")
Future (projected) P/E of the market segment - Neuro
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. This chart shows average profitability expectations for the biotech sector. CARA's position relative to the average reflects the market's opinion of the potential of its lead drug and the company's ability to address this unmet medical need.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772702451804 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Cara Therapeutics is a biopharmaceutical company developing and commercializing novel compounds targeting peripheral kappa opioid receptors for the treatment of itching and pain. This chart of overall market valuations shows how willing investors are to invest in companies solving specific but common medical problems with large markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702451807 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company developing treatments for pruritus associated with chronic diseases. Its financial chart reflects clinical trial expenses and revenue from the commercialization of its drug, KORSUVA. Successful sales are the key to future profitability.
Profit of companies in the market segment - Neuro
Cara Therapeutics develops drugs to treat itching associated with chronic kidney disease and other conditions. This is a highly specialized neurological niche. This chart shows the total revenue in its sector, illustrating the level of investor confidence in the commercial potential of its developments to treat complex neurological conditions and improve patients' quality of life.
Overall market profit
Cara Therapeutics develops innovative, non-addictive drugs for the treatment of itching and pain. The company's future depends on the success of its clinical trials. The overall market situation, reflected in this chart, directly impacts its ability to raise capital. During periods of growth, investors are more willing to fund long-term, risky scientific projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cara Therapeutics Inc.
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. The company's future profitability depends on the success of its lead drug and the expansion of its use. This chart shows analyst forecasts, which represent their assessment of the commercial potential in this specific but important therapeutic niche.
%20profit%20of%20the%20company%20Cara%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cara-Therapeutics-Inc.&v=1772702451863 "Graph of future (projected) profit of the company Cara Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Cara Therapeutics is developing new drugs to treat itching associated with chronic kidney disease and other conditions. The company's success depends on clinical trial results and the need for effective treatments for this symptom. This chart shows forecasts for the entire neuropharmaceutical sector, helping to assess the potential of Cara's developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772702451866 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Cara Therapeutics is developing drugs to treat itching. Like most biotech companies in the research stage, its value is determined by the potential of its research. The overall economic trends, which can be seen in this chart, are of minimal importance in assessing the company's prospects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702451867 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cara Therapeutics Inc.
Cara Therapeutics specializes in drugs for the treatment of neurological disorders. This chart illustrates the complex path from clinical trials to stable sales. Fluctuations in this indicator reflect the commercial success or failure of its products, as well as the market's assessment of the potential of future developments in its scientific pipeline.
P/S market segment - Neuro
Cara Therapeutics develops drugs that target itching and pain without targeting opioid receptors. Future revenue depends on the success of these developments. This chart for the neuroscience sector compares investor expectations for Cara's innovative platform with those of other companies working on new analgesics.
P/S of the market as a whole
Cara Therapeutics is a biopharmaceutical company developing treatments for itching associated with chronic diseases. This earnings valuation chart is important for understanding how investors view the company's potential to solve a medical problem that significantly impacts the quality of life for millions of people but often goes unaddressed.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company specializing in the development of treatments for itching associated with chronic diseases. This chart shows how the market perceives the future commercial potential of its drugs. It reflects investors' belief that the company's drugs will find their niche and be in demand for symptomatic relief.
%20P%2FS%20Cara%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cara-Therapeutics-Inc.&v=1772702451910 "The graph of the company's future (projected) P/S Cara Therapeutics Inc.")
Future (projected) P/S of the market segment - Neuro
Cara Therapeutics develops new drugs for the treatment of itching and pain by targeting peripheral kappa opioid receptors. This figure shows its estimated future revenue relative to other biopharmaceutical companies. This estimate reflects investors' faith in the potential of its scientific developments, despite past clinical trial failures.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772702451914 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. The company targets unmet medical needs. In the context of the overall revenue projections shown in the chart, Cara presents biotechnologies that improve patients' quality of life.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702451934 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company focused on the treatment of pruritus. Its revenue, shown in this chart, is generated by sales of KORSUVA, a drug intended for patients with chronic kidney disease on hemodialysis. Growth is driven by sales volume and affiliate royalties.
Sales of companies in the market segment - Neuro
Cara Therapeutics (CARA) is a biopharmaceutical company focused on developing treatments for pruritus associated with chronic kidney disease and dermatitis. This chart shows revenue in the neurosciences segment. Cara's innovations target debilitating symptoms, giving the company access to a significant and underserved market.
Overall market sales
Cara Therapeutics develops drugs to treat itching associated with various conditions. Its potential market depends on the introduction of new treatments into clinical practice. This pattern of overall economic activity impacts healthcare funding. A stable economy allows medical systems to more quickly adapt new, more effective therapeutic approaches.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cara Therapeutics Inc.
Cara Therapeutics is a biotech company focused on developing treatments for pruritus associated with chronic diseases. Future revenue depends on the success of its injectable Korsuva and the development of new formulations. This chart shows analyst sales forecasts, which assess the market potential and competitiveness of its therapy.
%20sales%20of%20the%20company%20Cara%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cara-Therapeutics-Inc.&v=1772702452024 "Schedule of future (projected) sales of the company Cara Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Neuro
Cara Therapeutics develops drugs to treat pruritus. The forecast in this chart reflects potential future revenue from their commercialized products and developments. It provides analysts' perspective on the size of the market for their therapy and their assessment of its ability to compete with other treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772702452039 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Cara Therapeutics develops drugs to treat itching associated with chronic diseases. Demand for these medications reflects a desire to improve patients' quality of life. This chart shows overall healthcare spending trends, and Cara's commercial success will depend on its ability to offer an effective solution to an unmet medical need.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702452057 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cara Therapeutics Inc.
Cara Therapeutics is a biopharmaceutical company developing treatments for chronic pruritus. At the forefront of science, its financial performance reflects significant investment in clinical research. The chart illustrates the company's financial journey as it strives to solve a complex medical problem and ultimately turn it into profit.
Market segment marginality - Neuro
Cara Therapeutics is a biopharmaceutical company developing treatments for pruritus associated with chronic diseases. This chart reflects its operating expenses during the clinical development and commercialization stages. The path to profitability depends on the success of its drugs and its ability to compete in the pharmaceutical market.
Market marginality as a whole
Cara Therapeutics develops medications to treat itching associated with chronic conditions. Demand for these medications depends on the breadth of insurance coverage. This graph, which shows overall profitability, affects the financial health of insurers. Their ability to include new drugs in their formularies determines the potential market for Cara's products.
Employees in the company, segment and market as a whole
Number of employees in the company Cara Therapeutics Inc.
Cara Therapeutics is a biotech company developing new treatments for pain and itching. Its focus is on scientific research. This graph shows the evolution of the team of scientists and clinicians advancing its leading developments through complex and lengthy clinical trials.
Share of the company's employees Cara Therapeutics Inc. within the market segment - Neuro
Cara Therapeutics develops new treatments for neurological diseases. In biotechnology, intellectual capital is the most important asset at the clinical trial stage. This chart shows the number of scientists and clinicians the company employs to conduct complex trials, a direct indicator of the intensity of its research and development.
Number of employees in the market segment - Neuro
Cara Therapeutics is developing new treatments for itching associated with various conditions. The employment dynamics in the neuroscience sector, visible in this graph, reflect the scale of sensory neuron research. For Cara, the growing number of scientists in this field means accelerated discovery, which could lead to both new opportunities and competitive developments.
Number of employees in the market as a whole
Cara Therapeutics develops new treatments for neurological disorders. The success of biopharmaceutical companies depends on investment in research. A healthy economy, illustrated by the growth in overall employment in this chart, creates a favorable environment for venture capital funding and allows large pharmaceutical companies to invest in R&D, supporting Cara's innovations.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cara Therapeutics Inc. (CARA)
Cara Therapeutics (CARA) develops neuroscience treatments. As with any biotech company, this chart shows the market's valuation of intellectual capital, not labor. The company's value lies in its patents and clinical trials. A high value indicates that investors are pricing in the future success of its drugs, which is independent of employee numbers.
%20of%20the%20company%20Cara%20Therapeutics%20Inc.%20(CARA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cara-Therapeutics-Inc.-CARA&v=1772702452185 "Chart of market capitalization per employee (in thousands of dollars) of the company Cara Therapeutics Inc. (CARA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Cara Therapeutics develops drugs for the treatment of neurological diseases. In this field, a company's value is derived from its intellectual property and its hopes for successful clinical trials. This chart shows the market premium for innovative potential per researcher working on new drugs.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772702452190 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Cara Therapeutics is a clinical-stage biotech developing drugs to treat itching. Its market cap is based on the potential of its research, not current sales. This chart for Cara illustrates how, in research-intensive industries, the market value per employee can be very high, reflecting investor expectations for future breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702452197 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cara Therapeutics Inc. (CARA)
Cara Therapeutics is a clinical-stage biotech company developing neurological drugs. The company is likely unprofitable. In that case, this graph would show a negative value—that is, the loss (investment) per employee. This reflects the burn rate of R&D capital in pursuit of scientific breakthroughs.
%20Chart%20Cara%20Therapeutics%20Inc.%20(CARA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cara-Therapeutics-Inc.-CARA&v=1772702452203 "Company Profit Per Employee (in thousands of dollars) Chart Cara Therapeutics Inc. (CARA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Cara Therapeutics focuses on developing non-addictive pain medications for the treatment of chronic diseases. In the field of neuroscience, the intellectual contribution of each scientist is invaluable. This chart reflects the financial productivity of its staff, which is an indicator of the effectiveness of the company's investment in research and its team.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772702452211 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Cara Therapeutics is a biopharmaceutical company specializing in the development of drugs to treat itching associated with chronic diseases (such as kidney disease). This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702452215 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cara Therapeutics Inc. (CARA)
Cara Therapeutics is a clinical-stage biopharmaceutical company developing drugs for neurological diseases. Because it has no commercial products yet, revenue per employee is minimal or nonexistent. This chart clearly illustrates the R&D phase, where all value is generated through research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cara-Therapeutics-Inc.-CARA&v=1772702452219 "Sales chart per company employee Cara Therapeutics Inc. (CARA)")
Sales per employee in the market segment - Neuro
Cara Therapeutics (CARA) is a biopharmaceutical company developing novel treatments for neurological conditions, particularly chronic pruritus (Korsuva). This metric reflects the average revenue per employee in the sector. It helps investors assess how effectively CARA utilizes its scientific and commercial staff to advance its research and development compared to other companies in the same niche.
Sales per employee for the market as a whole
Cara Therapeutics (CARA) is a biopharmaceutical company developing new treatments for itching associated with chronic diseases (e.g., kidney disease). The company is in the commercialization and further research phase. This metric reflects how successfully the company is marketing its drug, Korsuva, while simultaneously investing in R&D. It represents the balance between research costs and sales revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Cara Therapeutics Inc. (CARA)
Cara Therapeutics (CARA) suffered a major blow when its key drug, Korsuva, failed trials for atopic dermatitis. The company focused on narrower indications. This chart shows the level of mistrust. The high number of short positions reflects investor doubts about the value of the remaining pipeline and concerns about high cash burn. (346)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cara-Therapeutics-Inc.-CARA&v=1772702452226 "Short Shares Chart for the Company Cara Therapeutics Inc. (CARA)")
Shares shorted by market segment - Neuro
Cara Therapeutics (CARA) develops drugs to treat chronic itching associated with neurological and renal diseases. This is a niche position within the larger biotech sector. The chart below shows the total short position volume across the industry, an indicator of the overall market's confidence in the clinical success of these drugs.
Shares shorted by the overall market
Cara Therapeutics is a biotech with a long history of R&D, including failures in finding treatments for itching and pain. This chart illustrates the overall market pessimism. When investors are fearful, they are merciless to companies that have already "burned" them. The market doesn't give second chances and sells off shares, fearing the cash will run out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cara Therapeutics Inc. (CARA)
Cara Therapeutics (CARA) specializes in developing drugs to treat pruritus associated with chronic diseases, such as kidney disease. It's a narrow but in-demand niche. This chart measures the rate of price change. It shows when enthusiasm (above 70) about trial data or disappointment (below 30) peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cara-Therapeutics-Inc.-CARA&v=1772702452237 "RSI 14 indicator chart for the company's stock Cara Therapeutics Inc. (CARA)")
RSI 14 Market Segment - Neuro
Cara Therapeutics is a biotech company focused on treating pruritus associated with chronic conditions such as kidney disease (Korsuva). This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire segment is oversold.
RSI 14 for the overall market
For Cara Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CARA (Cara Therapeutics Inc.)
Cara Therapeutics is a biotech company focused on treating pruritus associated with chronic diseases (e.g., in dialysis patients). This chart shows the analysts' average 12-month forecast, reflecting their view on the commercial success of their drugs in this narrow but challenging niche.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CARA-Cara-Therapeutics-Inc.&v=1772702452250 "A chart showing analyst consensus forecasts for the expected stock price. CARA (Cara Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price CARA (Cara Therapeutics Inc.)
Cara (CARA) is a biotech company attacking the *itch* (pruritus). Their drug (Korsuva) targets a unique receptor to treat debilitating itching in dialysis patients. This chart shows how much upside or downside analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in this R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CARA-Cara-Therapeutics-Inc.&v=1772702452258 "A chart showing the difference between the consensus forecast and the actual stock price. CARA (Cara Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Cara Therapeutics (CARA) is a biotech company focused on the treatment of pruritus. Its drug Korsuva is approved for dialysis patients. This chart shows general expectations for the neurology (and dermatology) sector. It reflects whether experts believe the anti-itch market has the potential to expand.
Analysts' consensus forecast for the overall market share price
Cara Therapeutics (CARA) is a company that treats "itch." They don't treat pain, but rather specialize in chronic itching. Their drug (Korsuva) is approved for dialysis patients. This chart shows the overall risk appetite. It reflects investors' confidence in commercial success and the willingness of insurers to cover quality-of-life-improving drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cara Therapeutics Inc.
Cara is the king of itch. They're a biotech R&D company focused on pain and (their specialty) chronic itch. Their only approved drug (Korsuva) treats the excruciating itch of dialysis patients. This chart is a summary indicator of their niche market. It reflects their (meager) sales in this niche and their (failed) R&D efforts to expand its use.
AKIMA Market Segment Index - Neuro
Cara Therapeutics is a biopharmaceutical company focused on the neurological aspects of pain and itch. They develop drugs that target peripheral nerves rather than the brain (like opioids). This chart compares their composite index to the sector, showing how their non-opioid approach compares to others.
The AKIM Index for the overall market
Cara Therapeutics is a biopharmaceutical company developing drugs (Korsuva) to treat itching in patients with kidney disease. This chart, which reflects the market average, provides a macro backdrop. It helps assess how CARA, which addresses quality of life issues, compares to overall economic trends.
